Cite
Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study.
MLA
Foss-Freitas, Maria C., et al. “Selective Targeting of Angiopoietin-like 3 (ANGPTL3) with Vupanorsen for the Treatment of Patients with Familial Partial Lipodystrophy (FPLD): Results of a Proof-of-Concept Study.” Lipids in Health & Disease, vol. 20, no. 1, Dec. 2021, pp. 1–12. EBSCOhost, https://doi.org/10.1186/s12944-021-01589-4.
APA
Foss-Freitas, M. C., Akinci, B., Neidert, A., Bartlett, V. J., Hurh, E., Karwatowska-Prokopczuk, E., & Oral, E. A. (2021). Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study. Lipids in Health & Disease, 20(1), 1–12. https://doi.org/10.1186/s12944-021-01589-4
Chicago
Foss-Freitas, Maria C., Baris Akinci, Adam Neidert, Victoria J. Bartlett, Eunju Hurh, Ewa Karwatowska-Prokopczuk, and Elif A. Oral. 2021. “Selective Targeting of Angiopoietin-like 3 (ANGPTL3) with Vupanorsen for the Treatment of Patients with Familial Partial Lipodystrophy (FPLD): Results of a Proof-of-Concept Study.” Lipids in Health & Disease 20 (1): 1–12. doi:10.1186/s12944-021-01589-4.